You are here
P&T June 2016
Biosimilars are a highly anticipated arrival in the pharmacy. However, the undermanned and underfunded FDA struggles to guide, regulate, and approve them.
Biosimilars represent a potential savings opportunity for both payers and patients, but how and when the new agents will be accepted and prescribed is uncertain.
Investigators compare the 30-day all-cause readmission rate for 240 patients receiving either rivaroxaban or enoxaparin after total hip or total knee arthroplasty.
The authors examine the role that unregulated dietary supplements may have had in a young man who presented with psychotic and homicidal ideations.
The annual meeting of the AACR attracted 19,500 attendees in New Orleans in April. We review key scientific sessions on early clinical research, including immunotherapies.
Psoriasis, a disorder that manifests as a variety of chronic inflammatory skin diseases, affects an estimated 7.4 million Americans. We consider five promising biologic agents poised to enter the psoriasis market for advanced disease by 2019.
Muting alarms in the post-anesthesia care unit endangers patient safety
CMS Medicare Part B reimbursement plan panned
Approvals, new indications, regulatory activities, and more
Obiltoxaximab injection (Anthim) for anthrax infection; ixekizumab (Taltz) for psoriasis; and reslizumab (Cinqair) for severe asthma
Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist for type-2 diabetes